"10.1371_journal.pone.0116389","plos one","2015-01-05T00:00:00Z","Shiwen Peng; Joshua W Wang; Balasubramanyam Karanam; Chenguang Wang; Warner K Huh; Ronald D Alvarez; Sara I Pai; Chien-fu Hung; T -C Wu; Richard B S Roden","Department of Pathology, The Johns Hopkins University, Baltimore, Maryland, United States of America; Department of Biostatistics, The Johns Hopkins University, Baltimore, Maryland, United States of America; Department of Oncology, The Johns Hopkins University, Baltimore, Maryland, United States of America; Department of Gynecology and Obstetrics, The Johns Hopkins University, Baltimore, Maryland, United States of America; Division of Gynecologic Oncology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America; Department of Biology and Center for Cancer Research, Carver Research Foundation, Tuskegee University, Tuskegee, Alabama, United States of America; Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, United States of America","Conceived and designed the experiments: WKH RDA SIP CFH TCW RBSR. Performed the experiments: SP JWW BK CFH. Analyzed the data: SP JWW BK CW WKH RDA SIP CFH TCW RBSR. Wrote the paper: SP CW WKH RDA SIP CFH TCW RBSR.","RBSR is an inventor of L2-related patents (US application 20090047301 Papillomavirus L2 N-Terminal Peptides for the Induction of Broadly Cross-Neutralizing Antibodies and US application 20130177585 PAPILLOMAVIRUS L2 N-TERMINAL PEPTIDES FOR THE INDUCTION OF BROADLY CROSS-NEUTRALIZING ANTIBODIES) licensed to Shantha Biotechnics Ltd., GlaxoSmithKline, PaxVax, Inc. and Acambis, Inc. RBSR and TCW are founders of Papivax LLC and scientific advisors to Papivax Biotech Inc. The terms of these arrangements are managed by Johns Hopkins University in accordance with its conflict of interest policies. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.","2015","01","Shiwen Peng","SP",10,TRUE,6,4,10,8,TRUE,TRUE,FALSE,0,NA,FALSE
